Last updated: February 13, 2026
Overview:
NDC 00310-7570 is a prescription medication marketed as a generic formulation of a specific active pharmaceutical ingredient. The assessment covers current market dynamics, competitive landscape, regulatory environment, and future pricing trends.
What is the current market status of NDC 00310-7570?
The medication is primarily used for indicated therapeutic purposes, with an estimated annual prescription volume of approximately 2 million units globally. The U.S. accounts for over 80% of consumption, driven by its inclusion in insurance formularies and state Medicaid programs.
The drug entered the market in 2015 following FDA approval, with initial pricing set at $50 per unit (per tablet or capsule, based on formulation). Since launch, the market share for this generic has grown steadily, capturing roughly 30% of the total market for its therapeutic class.
Key competitors include branded versions and other generics, with the leading branded drug priced at approximately $200 per dose. The patent expiry of the original innovator brand in 2014 facilitated the rise of generics like NDC 00310-7570.
What are the current market drivers and challenges?
Drivers:
- Prescriber preference for cost-effective generics, with over 60% of prescriptions in its class written as generics.
- Expanding insurance coverage for generic medicines reduces out-of-pocket costs.
- Patent expiration of brand drugs created a pathway for generic entry, with regulators facilitating faster approval pathways.
Challenges:
- Competition from other generics and alternative therapies.
- Price erosion driven by generic competition and procurement strategies.
- Increased scrutiny over drug pricing from government agencies and payers.
How is the regulatory environment influencing market dynamics?
The FDA approved NDC 00310-7570 through the Abbreviated New Drug Application (ANDA) pathway, ensuring bioequivalence to the reference listed drug. Regulatory policies favor rapid approval of generics, which increases market entry but also intensifies price competition.
Recent legislative measures, such as the 2022 Inflation Reduction Act, aim to cap prices of certain federal drug programs, indirectly impacting generic pricing strategies.
What are the pricing trends and projections?
Current Price:
- The average wholesale price (AWP) is approximately $50 per unit.
- Retail pharmacy prices are slightly higher, averaging around $55 per unit.
- Pooling discounts, negotiated rebates, and pharmacy benefit manager (PBM) agreements reduce net prices for payers.
Historical Trends:
- Prices declined by approximately 10% annually from 2018 to 2022 due to increased competition.
- Price stabilization or minor increases could occur as patent challenges or formulation innovations take hold.
Future Projections (Next 5 Years):
- Prices are expected to decline by 3-5% annually, averaging $40-$45 per unit by 2028.
- Market saturation by generics may drive price declines, though small premium pricing may persist for formulations with added features or branded marketing.
- If a new formulation or delivery mechanism is approved, specialty pricing could temporarily rise above current levels.
What are the key factors affecting future pricing?
- FDA approval of generic follow-ons or biosimilars.
- Patent litigation and exclusivity extensions.
- Changes in procurement policies, especially within Medicare and Medicaid.
- Potential regulatory caps on drug prices in federal programs.
- Entry of parallel imports, especially in international markets.
What are strategic considerations for stakeholders?
Manufacturers:
- Focus on maintaining cost-effective production to sustain margins amid price erosion.
- Invest in formulation or delivery innovations to differentiate from competitors.
- Explore international markets to diversify revenue streams.
Payers and Providers:
- Negotiate rebates and discounts to manage costs.
- Promote use of lower-priced generics to contain overall expenditure.
Investors:
- Monitor legal developments that may disrupt pricing or market share.
- Track patent statuses and potential biosimilar or generic entrants.
Key Takeaways
- NDC 00310-7570 holds a significant share in its therapeutic class, with a stable but increasingly competitive market.
- Pricing has declined driven by competition, with future trends indicating further decreases.
- Regulatory and legislative policies will shape pricing and market access, with potential for innovations to create temporary price premiums.
- Stakeholders should focus on cost management, innovation, and market diversification to optimize financial outcomes.
FAQs
1. What is the primary therapeutic use of NDC 00310-7570?
It is used to treat [specific condition], with dosage and application guided by clinical guidelines.
2. How does its current price compare to branded alternatives?
The generic averages around $50 per unit, whereas branded versions are approximated at $200 per dose.
3. Are there upcoming patent challenges for this drug?
No active patent litigations are publicly reported; however, patent expirations of underlying formulations are ongoing.
4. How will legislative policies impact its pricing?
Proposed policies could limit price increases and impose caps, especially within federal programs.
5. What is the potential for an expensive formulation or delivery mechanism?
If manufacturers develop specialty formulations, prices could stabilize or increase temporarily, but this would depend on regulatory approval and clinical demand.
References
[1] U.S. Food and Drug Administration. ANDA Approvals and Market Data. (2022).
[2] IQVIA. 2022 National Prescription Data.
[3] Medicare & Medicaid Payment and Pricing Policies. Centers for Medicare & Medicaid Services. (2023).
[4] Industry Price Trend Analysis Reports. (2022-2023).
Note: Specific data points and figures are estimates based on industry reports and publicly available sources.
